HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPA Board Members Argue Investigating The CEO Was Part Of Their Job

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

NPA's amended complaint includes a purported email trail showing the self-professed "shadow board" plotted to remove CEO Daniel Fabricant. In a motion to dismiss, board members argue that while NPA alleges "a breach of fiduciary duty … they satisfied, rather than violated, their fiduciary duties."

You may also be interested in...



NPA's Former CFO Alleges Improper Expenses By Fabricant, Religious And Gender Harassment

CEO Daniel Fabricant and the NPA board's president say former CFO Brent Weickert's allegations in a complaint filed in California state court are baseless. Weickert, with NPA from 1997 until October, says he was dismissed after he stated his concerns to NPA's board and to Fabricant.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade

Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel